Literature DB >> 8831468

Subacute methylphenidate treatment for moderate to moderately severe traumatic brain injury: a preliminary double-blind placebo-controlled study.

P M Plenger1, C E Dixon, R M Castillo, R F Frankowski, S A Yablon, H S Levin.   

Abstract

OBJECTIVE: To determine the effect of subacute administration of methylphenidate on recovery from moderate to moderately severe closed head injury.
DESIGN: Double-blind placebo-controlled with random assignment. Patients were enrolled when their Galveston Orientation and Amnesia Test score was at least 65. Drug/placebo treatment began the day following baseline cognitive assessment and continued for 30 consecutive days. Follow-up evaluations were conducted at 30 and 90 days after baseline, after discontinuation of drug/placebo.
SETTING: A level I trauma center. PATIENTS: Twenty-three patients ranging in age from 16 to 64 years. Head injury severity ranged from moderately severe (Glasgow Coma Score [GCS] < or = 8, no intracranial pressure monitor) to "complicated mild" (GCS from 13 to 15 with positive computed tomography brain scan). Thirty-day follow-up was based on 12 patients, whereas 90-day evaluation was based on 9 patients, with complicated mild head injuries excluded from the analyses.
INTERVENTIONS: Methylphenidate administered twice daily at a dose of .30 mg/kg; placebo administered according to the same schedule in identical pill form. MAIN OUTCOME MEASURES: The Disability Rating Scale (DRS) and tests of attention, memory, and vigilance.
RESULTS: The methylphenidate group was significantly better at 30 days on the DRS (p < .02), and on tests of attention (p < .03) and motor performance (p, .05). No significant differences were noted between groups at 90 days.
CONCLUSIONS: Subacute administration of methylphenidate after moderately severe head injury appeared to enhance the rate but not the ultimate level of recovery as measured by the DRS and tests of vigilance. Problems with possible selection bias and small sample size limit generalization of results.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8831468     DOI: 10.1016/s0003-9993(96)90291-9

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  30 in total

Review 1.  Medical therapies for concussion.

Authors:  William P Meehan
Journal:  Clin Sports Med       Date:  2011-01       Impact factor: 2.182

Review 2.  Catecholaminergic based therapies for functional recovery after TBI.

Authors:  Nicole D Osier; C Edward Dixon
Journal:  Brain Res       Date:  2015-12-19       Impact factor: 3.252

3.  Differential effects of single versus multiple administrations of haloperidol and risperidone on functional outcome after experimental brain trauma.

Authors:  Anthony E Kline; Jaime L Massucci; Roos D Zafonte; C Edward Dixon; Judith R DeFeo; Emily H Rogers
Journal:  Crit Care Med       Date:  2007-03       Impact factor: 7.598

Review 4.  Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults.

Authors:  Susan E Hardy
Journal:  Am J Geriatr Pharmacother       Date:  2009-02

5.  Administration of haloperidol and risperidone after neurobehavioral testing hinders the recovery of traumatic brain injury-induced deficits.

Authors:  Ann N Hoffman; Jeffrey P Cheng; Ross D Zafonte; Anthony E Kline
Journal:  Life Sci       Date:  2008-08-31       Impact factor: 5.037

6.  Methylphenidate modulates sustained attention and cortical activation in survivors of traumatic brain injury: a perfusion fMRI study.

Authors:  Junghoon Kim; John Whyte; Sunil Patel; Eduardo Europa; Jiongjiong Wang; H Branch Coslett; John A Detre
Journal:  Psychopharmacology (Berl)       Date:  2011-12-28       Impact factor: 4.530

7.  Methylphenidate and Memory and Attention Adaptation Training for Persistent Cognitive Symptoms after Traumatic Brain Injury: A Randomized, Placebo-Controlled Trial.

Authors:  Brenna C McDonald; Laura A Flashman; David B Arciniegas; Robert J Ferguson; Li Xing; Jaroslaw Harezlak; Gwen C Sprehn; Flora M Hammond; Arthur C Maerlender; Carrie L Kruck; Karen L Gillock; Kim Frey; Rachel N Wall; Andrew J Saykin; Thomas W McAllister
Journal:  Neuropsychopharmacology       Date:  2016-11-22       Impact factor: 7.853

8.  Effect of growth hormone replacement therapy on cognition after traumatic brain injury.

Authors:  Walter M High; Maria Briones-Galang; Jessica A Clark; Charles Gilkison; Kurt A Mossberg; Dennis J Zgaljardic; Brent E Masel; Randall J Urban
Journal:  J Neurotrauma       Date:  2010-09       Impact factor: 5.269

Review 9.  5-hydroxytryptamine1A (5-HT1A) receptor agonists: A decade of empirical evidence supports their use as an efficacious therapeutic strategy for brain trauma.

Authors:  Jeffrey P Cheng; Jacob B Leary; Aerin Sembhi; Clarice M Edwards; Corina O Bondi; Anthony E Kline
Journal:  Brain Res       Date:  2015-11-21       Impact factor: 3.252

Review 10.  Pharmacotherapy of traumatic brain injury: state of the science and the road forward: report of the Department of Defense Neurotrauma Pharmacology Workgroup.

Authors:  Ramon Diaz-Arrastia; Patrick M Kochanek; Peter Bergold; Kimbra Kenney; Christine E Marx; Col Jamie B Grimes; L T C Yince Loh; L T C Gina E Adam; Devon Oskvig; Kenneth C Curley; Wanda Salzer
Journal:  J Neurotrauma       Date:  2014-01-15       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.